Neurological Biomarkers Market Size

Neurological Biomarkers Market Size

The global neurological biomarkers market size was valued at USD 9.5 billion in 2024 and is estimated to grow at a CAGR of 10.9% from 2025 to 2034. Neurological conditions, including Alzheimer's, Parkinson's, and other neurodegenerative diseases, are on the rise globally.

To get key market trends

  Download Free Sample

This trend is primarily attributed to an aging population, with Alzheimer's becoming increasingly common among older adults. As a result, the growing prevalence of neurological disorders has significantly boosted the demand for personalized medicine, thereby driving the expansion of the neurological biomarkers market. Furthermore, the market is being strengthened by advancements in genomics, proteomics, and imaging technologies for diagnosing neurological conditions. Biomarkers that detect specific brain proteins, genes, or metabolites allow for more accurate and earlier diagnoses, potentially leading to better treatment outcomes.

For instance, in July 2024, Biogen, Beckman Coulter, and Fujirebio announced a collaboration aimed at identifying and developing blood-based biomarkers for tau pathology in the brain. This initiative could lead to the clinical advancement and commercialization of new tests for tau pathology in Alzheimer’s disease (AD). Thus, the development of tau-specific blood-based biomarkers that can measure a patient’s tau burden could provide critical insights into the underlying pathological processes of AD and support the development of a new generation of therapies, fueling market growth.

Neurological biomarkers are biological indicators that assess the presence, severity, or progression of neurological diseases. These markers are typically molecules, genes, or other substances found in the brain or blood that reflect underlying neurological conditions. Examples include biomarkers for Alzheimer's disease, Parkinson's disease, multiple sclerosis, and autism spectrum disorders.